Drug intelligence / Profile preview

AGS-1010

Development stage: Preclinical
Lead developer: AGS Tx
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

AGS-1010 is an experimental therapeutic candidate developed by AGS Therapeutics for the treatment of wet age-related macular degeneration (wAMD) and other neovascularization processes. The drug utilizes a proprietary delivery platform based on Membrane Extracellular Vesicles (MEVs) derived from the microalgae *Chlorella*. These MEVs serve as lipid-bilayer nanoparticles capable of encapsulating various anti-angiogenic payloads, including mRNAs, siRNAs, proteins, and peptides. AGS-1010 is designed for non-invasive administration via eye drops, aiming to deliver therapeutic molecules directly to the back of the eye, thereby providing a potential alternative to traditional intravitreal injections.

Beyond the preview

Go deeper on AGS-1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGS-1010.

Explore the full profile